metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Aproximación A. Tratamiento empírico con inhibidores de la bomba de protones y...
Información de la revista
Vol. 31. Núm. S2.
Avances y controversias en el diagnóstico y tratamiento de enfermedades relacionadas con el ácido
Páginas 23-26 (junio 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 31. Núm. S2.
Avances y controversias en el diagnóstico y tratamiento de enfermedades relacionadas con el ácido
Páginas 23-26 (junio 2008)
Avances y controversias en el diagnóstico y tratamiento de enfermedades relacionadas con el ácido
Acceso a texto completo
Aproximación A. Tratamiento empírico con inhibidores de la bomba de protones y después de mantenimiento
Visitas
1737
Enrique Rey
Autor para correspondencia
rey.enrique.spain@gmail.com

Correspondencia: E. Rey. Servicio de Aparato Digestivo. Hospital Clinico San Carlos. Martin Lagos, s/n. Madrid 28040. España.
Servicio de Aparato Digestivo. Hospital Clínico San Carlos. Universidad Complutense. Madrid. España
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Díaz-Rubio, C. Moreno-Elola-Olaso, E. Rey, et al.
Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population.
Aliment Pharmacol Ther, 19 (2004), pp. 95-105
[2.]
J. Ponce, O. Vegazo, B. Beltran, et al.
Prevalence of gastro-oesophageal reflux disease in Spain and associated factors.
Aliment Pharmacol Ther, 23 (2006), pp. 175-184
[3.]
M.C. Aanen, B.L. Weusten, M.E. Numans, et al.
Diagnostic value of the proton pump inhibitor test for gastro-oesophageal reflux disease in primary care.
Aliment Pharmacol Ther, 24 (2006), pp. 1377-1384
[4.]
A.G. Klauser, N.E. Schindlbeck, SA. Muller-Lissner.
Symptoms in gastro-oesophageal reflux disease.
Lancet, 335 (1990), pp. 205-208
[5.]
L. Tefera, M. Fein, M.P. Ritter, et al.
Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease?.
Am Surg, 63 (1997), pp. 933-936
[6.]
J.H. Wang, J.Y. Luo, L. Dong, et al.
Composite score of reflux symp toms in diagnosis of gastroesophageal reflux disease.
World J Gastroenterol, 10 (2004), pp. 3332-3335
[7.]
D. Armstrong, J.K. Marshall, N. Chiba, et al.
Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004.
Can J Gastroenterol, 19 (2005), pp. 15-35
[8.]
K.R. DeVault, D.O. Castell.
Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.
Am J Gastroenterol, 100 (2005), pp. 190-200
[9.]
K.M. Fock, N. Talley, R. Hunt, et al.
Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease.
J Gastroenterol Hepatol, 19 (2004), pp. 357-367
[10.]
M. Marzo, P. Alonso, X. Bonfill, et al.
Clinical practice guideline on the management of patients with gastroesophageal reflux disease (GERD).
Gastroenterol Hepatol, 25 (2002), pp. 85-110
[11.]
J. Moraes-Filho, I. Cecconello, J. Gama-Rodrigues, et al.
Brazilian consensus on gastroesophageal reflux disease: proposals for assessment, classification, and management.
Am J Gastroenterol, 97 (2002), pp. 241-248
[12.]
T. Mantynen, M. Farkkila, I. Kunnamo, et al.
The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year crosssectional study in a referral area with 260,000 inhabitants.
Am J Gastroenterol, 97 (2002), pp. 2524-2529
[13.]
S.J. Panter, H. O’Flanagan, M.G. Bramble, et al.
Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome.
Aliment Pharmacol Ther, 19 (2004), pp. 981-988
[14.]
P.B. Van, M.E. Numans, P.A. Bonis, et al.
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
Cochrane Database Syst Rev, 4 (2004),
[15.]
M.B. Fennerty, J.F. Johanson, C. Hwang, et al.
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
Aliment Pharmacol Ther, 21 (2005), pp. 455-463
[16.]
N.J. Talley, A.L. Weaver, A.R. Zinsmeister, et al.
Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders.
Am J Epidemiol, 136 (1992), pp. 165-177
[17.]
W.M. Wong, K.C. Lai, K.F. Lam, et al.
Onset and disappearance of reflux symptoms in a Chinese population: a 1-year follow-up study.
Aliment Pharmacol Ther, 20 (2004), pp. 803-812
[18.]
D.J. Hetzel, J. Dent, W.D. Reed, et al.
Healing and relapse of severe peptic esophagitis after treatment with omeprazole.
Gastroenterology, 95 (1988), pp. 903-912
[19.]
J. Labenz, M. Nocon, T. Lind, et al.
Prospective follow-up data from the ProGERD study suggest that GERD is not a categorical disease.
Am J Gastroenterol, 101 (2006), pp. 2457-2462
[20.]
C.E. Macdonald, A.C. Wicks, R.J. Playford.
Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study.
BMJ, 321 (2000), pp. 1252-1255
[21.]
V.F. Eckardt, G. Kanzler, G. Bernhard.
Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation.
Am J Med, 111 (2001), pp. 33-37
[22.]
N.E. Schindlbeck, A.G. Klauser, G. Berghammer, et al.
Three year follow up of patients with gastrooesophageal reflux disease.
Gut, 33 (1992), pp. 1016-1019
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos